

Biocatalytic Dynamic Kinetic Resolution for the Synthesis of Atropisomeric Biaryl N-Oxide Lewis Base Catalysts

Samantha Staniland, Ralph W. Adams, Joseph J. W. McDouall, Irene Maffucci, Alessandro Contini, Damian M. Grainger, Nicholas J. Turner,* and Jonathan Clayden*

Abstract: Atropisomeric biaryl pyridine and isoquinoline N-oxides were synthesized enantioselectively by dynamic kinetic resolution (DKR) of rapidly racemizing precursors exhibiting free bond rotation. The DKR was achieved by ketoreductase (KRED) catalyzed reduction of an aldehyde to form a configurationally stable atropisomeric alcohol, with the substantial increase in rotational barrier arising from the loss of a bonding interaction between the N-oxide and the aldehyde. Use of different KREDs allowed either the M or P enantiomer to be synthesized in excellent enantiopurity. The enantioenriched biaryl N-oxide compounds catalyze the asymmetric allylation of benzaldehyde derivatives with allyltrichlorosilane.

Biaryl atropisomers provide an important class of structure with extensive utility in asymmetric synthesis, particularly as ligands inducing asymmetric catalysis by metals.^[1] Atropisomers are also used as catalysts in their own right. BINOL-derived phosphoric acids have been utilized as Brønsted acid catalysts,^[2] and atropisomeric quinoline N-oxides such as QUINOX^[3] are excellent Lewis base catalysts for various asymmetric transformations including asymmetric allylation of substituted benzaldehydes,^[4,5] asymmetric desymmetrizations of meso epoxides,^[6] and asymmetric aldol reactions.^[7]

The need for efficient methods for the enantioselective synthesis of atropisomers^[8] has encouraged the development of atropselective transition-metal couplings,^[9] kinetic resolution by metal catalysis^[10] and organocatalytic methods,^[11] and

desymmetrization.^[12] The potential for subtle control of racemization rates in atropisomeric and near-atropisomeric structures allows the efficient use of dynamic kinetic^[13] or thermodynamic^[14] resolution. Although biocatalytic methods are particularly effective for achieving kinetic resolution and dynamic kinetic resolution,^[15] biocatalytic dynamic kinetic resolution (DKR) has never been used to synthesize atropisomers enantioselectively.^[16] Herein we describe the first use of biocatalytic DKR for the asymmetric synthesis of some novel catalytically active biaryl atropisomers.

In an effective DKR,^[17] an enantioselective transformation must take place more slowly than the racemization of the starting materials but faster than the racemization of the products. This requirement makes DKR a particularly appealing strategy for the synthesis of atropisomers, since their racemization entails a simple bond rotation which may be fine-tuned using steric or electronic substituent effects. For a practical biocatalytic DKR this substrate racemization must take place on a timescale of minutes or less, within a temperature range at which the enzyme can operate (typically 20–50°C), while the product must be atropisomerically stable over, at least, a time period of hours at this temperature. We reasoned that such a substantial decrease in racemization rate could be achieved by a functional-group interconversion in which a small, planar substituent, such as an aldehyde, is converted into a larger, tetrahedral substituent.^[18] Atropisomeric alcohols of the general structure **3** (see Scheme 1) are useful chiral ligands for asymmetric synthesis,^[19] so we set out to explore the possibility of making them enantioselectively by dynamic kinetic resolution of the biaryl aldehydes **1**.

Initial studies focused on the aldehyde **1a**, but this turned out to be unstable towards an oxidative cyclization (see the Supporting Information), so its isoquinoline nitrogen atom was protected in the form of the N-oxide derivative **2a** (Scheme 1). Suzuki coupling of the boronate ester **6** with 1-bromoisoquinoline (**5**) in 86% yield was followed by THP ether removal to give **3a** in 73% yield. Oxidation to the N-oxide **4a** in 74% yield and a second oxidation with MnO₂ gave **2a** in 86% yield. The stability of **2a** towards racemization was estimated by micropreparative separation of its enantiomers by HPLC on a chiral stationary phase, monitoring the subsequent decay in *ee* value of **2a** over time. No loss in *ee* value was observed after 5 hours in xylenes at 100°C, and at 138°C decomposition occurred faster than racemization. A substrate racemizing this slowly is not a suitable candidate for a DKR process, so **2a** was used instead as a model to determine the ability of commercially available ketoreductase enzymes (KREDs) to distinguish the enantiomers of this family of biaryl aldehydes in a non-dynamic

[*] Dr. S. Staniland, Dr. R. W. Adams, Dr. J. J. W. McDouall
School of Chemistry, University of Manchester
Manchester M13 9PL (UK)


Dr. I. Maffucci, Dr. A. Contini
Università di Milano, Dipartimento Scienze Farmaceutiche—Sezione
di Chimica Generale e Organica “Alessandro Marchesini”
Università degli Studi di Milano, 20133 Milano (Italy)

Dr. D. M. Grainger
Johnson Matthey Catalysis and Chiral Technologies
Cambridge, CB4 0FP (UK)

Prof. N. J. Turner
School of Chemistry, University of Manchester
Manchester Institute of Biotechnology
131 Princess Street, Manchester M1 7DN (UK)
E-mail: nicholas.turner@manchester.ac.uk

Prof. J. Clayden
School of Chemistry, University of Bristol
Cantock's Close, Bristol BS8 1TS (UK)
E-mail: j.clayden@bristol.ac.uk

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under <http://dx.doi.org/10.1002/anie.201605486>.



Scheme 1. Biaryl aldehyde substrates for KR and DKR. a) [PdRuPhos] (3 mol %), CsF (3.0 equiv), THF, reflux, 86%; b) PPTS (0.6 equiv), EtOH, 73%; c) MnO_2 (10.0 equiv), CH_2Cl_2 , RT, 86%; d) *m*CPBA (1.5 equiv), CH_2Cl_2 , RT, 74%. *m*CPBA = *m*-chloroperbenzoic acid, PPTS = pyridinium *para*-toluenesulfonate, THF = tetrahydrofuran, THP = tetrahydropyran.


kinetic resolution. The aldehyde **2a** was incubated at 30 °C for 16 hours with a series of KREDs in the presence of a glucose/glucose dehydrogenase (GDH)/NADP cofactor recycling system,^[20] and the results are shown in Table 1. KREDs (Codexis) 113, 110, 112, and 114 (entries 5, 7, 8, and 9) gave excellent results, selectively reducing one enantiomer of **2a** to give the alcohol **4a** with *ee* values ranging from 98 to greater than 99%, and with yields of 46–51%. KRED 130, by contrast, (entry 13) showed high reactivity but low enantioselectivity, and produced **4a** in 93% yield with 20% *ee*. These high enantioselectivities indicated that the enzyme active site was able to distinguish highly effectively the two enantiomeric atropisomers of a 2-arylisoquinoline-*N*-oxide, so we set about modifying the substrates to increase the rate of racemization of these substrates.

Table 1: Kinetic resolution of (±)-**2a** using a panel of KREDs.

Entry	KRED	(±)- 2a → 4a (KRED, 30 °C, 16 h)		+ 2a	
		Conv. [%] ^[a]	<i>ee</i> [%] ^[b]	Conv. [%]	<i>ee</i> [%] ^[b]
1	102	4	22	96	0
2	105	0	–	100	–
3	107	0	–	100	–
4	108	3	60	97	3
5	110	54	63	46	98
6	111	0	–	100	–
7	112	51	67	49	99
8	113	54	65	46	> 99
9	114	49	77	51	98
10	119	40	87	60	72
11	123	31	72	69	45
12	124	62	44	38	99
13	130	93	1	7	20
14	none ^[c]	13	100	87	23

[a] Conversion determined by HPLC. [b] Absolute configuration not known. The *ee* value was determined by HPLC on a chiral stationary phase. [c] Reaction mixture still contains GDH.

Two less-hindered biaryl *N*-oxides, the 1-phenylisoquinoline-*N*-oxide (**2b**), and the 2-(1-naphthyl)pyridine-*N*-oxide (**2c**), were made by Suzuki coupling (Scheme 2). Preliminary




Scheme 2. Synthesis of less-hindered biaryl *N*-oxide aldehydes **2b,c** and alcohols **4b,c**, along with the models **7** and **8**. $\Delta G^\ddagger$ indicates the barrier to Ar–Ar bond rotation at the indicated temperature in Kelvin. a) [Pd(PPh₃)₄] (10 mol %), K₂CO₃ (3.0 equiv), 1,4-dioxane, reflux; b) NaBH₄, MeOH.

analysis by HPLC suggested that both aldehydes were unstable towards racemization at room temperature: attempted resolution on a chiral stationary phase at 30 °C resulted in a single broad peak in both cases. By contrast, racemic samples of the corresponding alcohols **4b** and **4c** each clearly showed two distinct enantiomeric peaks on the same chiral stationary phase (see the Supporting Information), indicating that, as hoped, both **4b** and **4c** had a substantially higher barrier to rotation than the corresponding aldehydes.

The rotational barriers of the configurationally unstable **2b** and **2c** were determined more accurately by variable-temperature (VT) ¹H NMR analysis in [D₈]toluene in the presence of the chiral solvating reagent (*R*)-1-anthracen-9-yl-2,2,2-trifluoroethanol (1 equiv). VT-NMR spectroscopy and line-shape analysis of the resulting pair of diastereoisomeric aldehyde CHO resonances (see the Supporting Information) gave values for the barrier to enantiomerization of $\Delta G^\ddagger_{298\text{ K}} = 68.1\text{ kJ mol}^{-1}$ for **2b** and $\Delta G^\ddagger_{298\text{ K}} = 65.7\text{ kJ mol}^{-1}$ for **2c**, both corresponding to half-lives of seconds or less at ambient temperatures. The barriers to Ar–Ar bond rotation in **4b** and **4c** were calculated from the rate of first-order decay in *ee* value, of samples resolved by semi-preparative HPLC on a chiral stationary phase over time, at 90 °C in xylenes (see the Supporting Information). For **4b** $\Delta G^\ddagger_{363\text{ K}} = 120.7\text{ kJ mol}^{-1}$, corresponding to a half-life of 2.9 hours to racemization at 90 °C, and for **4c**, $\Delta G^\ddagger_{363\text{ K}} = 115.1\text{ kJ mol}^{-1}$, corresponding to a half-life of 45 minutes to racemization at 90 °C. The substantially greater configurational stability of the alcohols over the aldehydes allows a usefully large window for a potential dynamic kinetic resolution on a time-scale intermediate between the two time scales of racemization.

The panel of KREDs were screened against **2b** and **2c** on an analytical scale (1 mL, 2.5 mg substrate). Remarkably, KREDs 108, 112, 119, and 130 (Table 2, entries 4, 7, 9, and 12)


Table 2: Dynamic kinetic resolution of ($\pm$)-**2b** using a panel of KREDs.


Entry	KRED	4b		Config. ^[c]
		Conv. [%] ^[a]	ee [%] ^[b]	
1	102	21	7	R
2	105	4	> 99	R
3	107	5	> 99	R
4	108	100	96	S
5	110	59	99	S
6	111	5	> 99	R
7	112	100	98	S
8	113	93	95	S
9	119	100	94	S
10	123	22	16	S
11	124	73	68	S
12	130	100, 83 ^[d]	> 99	R
13	none	0	—	—

[a] Conversion determined by HPLC. [b] The *ee* value was determined by HPLC on a chiral stationary phase. [c] Configuration assigned by comparing experimental and calculated circular dichroism spectra (see Figure 1). [d] Yield of product isolated from a reaction run on 500 mg scale.


performed almost perfect DKRs of **2b**. The atropisomeric alcohol (*S*)-**4b** was obtained in 100% yield (based on full conversion by HPLC), with enantioselectivities of 96, 98, and 94% *ee*. Furthermore, KRED 130, (entry 12) showed opposite selectivity to KREDs 108, 112, and 119 (entries 4, 7 and 9), giving (*R*)-**4b** with an excellent *ee* value (> 99%). The ability to access both enantiomers of the product is an attractive feature of the method, and scaling the reaction to 500 mg of substrate (entry 12) returned a preparatively useful quantity of (*R*)-**4b**. This result represents the first example of a biocatalytic DKR for the asymmetric synthesis of an enantiopure axially chiral biaryl. A control experiment in the absence of KRED (entry 13) confirmed that the background reduction by the glucose dehydrogenase (GDH) used for cofactor recycling was not responsible for the DKR.

The substrate **2c** was screened with the same series of KREDs and again excellent conversions (100%) were obtained, this time with KREDs 110, 112, 113, 124, and 130 (Table 3, entries 5, 7, 8, 11, and 12). In general the enantioselectivities were lower than with **2b**, but nonetheless KRED 130 (entry 12) produced (*S*)-**4c** in 96% *ee* and 100% yield. In this case, a background reaction occurred in the absence of the KRED (entry 13), suggesting that GDH was able to catalyze the reduction in 3% yield and 36% *ee*. GDH is known to have some substrate promiscuity,^[21] so the reaction was repeated using formate dehydrogenase (FDH) and formic acid as the cofactor recycling system. No background reaction was observed (entry 14). The enantioselectivity with KRED 130 with FDH recycling remained high (96% *ee*), so any background reaction from using GDH can be disregarded. Again, the reaction performed well on scale-

Table 3: Dynamic kinetic resolution of ($\pm$)-**2c** using a panel of KREDs.


Entry	KRED	4c		Config. ^[c]
		Conv. [%] ^[a]	ee [%] ^[b]	
1	102	21	55	S
2	105	5	76	S
3	107	11	33	R
4	108	21	82	S
5	110	100	4	R
6	111	25	74	S
7	112	100	54	S
8	113	100	8	R
9	119	77	23	S
10	123	7	11	S
11	124	100	73	R
12	130	100, 73 ^[d]	96	S
13	none	3	36	S
14	none ^[e]	0	—	—
15	130 ^[e]	42	96	S

[a] Conversion determined by HPLC. [b] The *ee* value was determined by HPLC on a chiral stationary phase. [c] Configuration assigned by comparing experimental and calculated circular dichroism spectra (see Figure 1). [d] Yield of product isolated from reaction run on 500 mg scale. [e] Formate dehydrogenase (FDH) used instead of GDH, with formic acid as reductant.

**Figure 1.** Experimental (solid line) and calculated (dashed line) electronic circular dichroism spectra for a) (*R*)-**4b** and b) (*S*)-**4c**.

up, giving 73% of (*S*)-**4c** (96% *ee*) on a 500 mg scale (entry 12).

The absolute configurations of **4b** and **4c** were assigned by comparison of their electronic circular dichroism spectra

(Figure 1, solid lines) with CD spectra calculated by time-dependent DFT (Figure 1, dashed lines; see the Supporting Information). Intriguingly, KRED 130 reduced **2b** to give (*R*)-**4b**, but reduced **2c** to give (*S*)-**4c**.

The successful DKR is made possible by the substantial difference in barriers to Ar–Ar bond rotation between the aldehydes **2** and the alcohols **4**. To explore the possibility that a bonding interaction between the N-oxide substituent and the formyl group in **2** accelerates this racemization (Figure 2),^[22] isosteric fluorinated compounds **7** and **8** were





Figure 2. Bonding interaction at the transition state for enantiomerization of **2**.

made (Scheme 2), because in these structures this possibility for interaction is greatly reduced. While the barrier to bond rotation in **8** is similar to that in the alcohols **4**, the barrier to bond rotation in **7** is significantly higher than that in **2**, suggesting that the transition state for enantiomerization of **2** benefits from the stabilizing bonding interaction illustrated in Figure 2. Molecular modelling (described in full in the Supporting Information) supports this interpretation, indicating pyramidalization of the aldehyde at the transition state (Figure 2) as a consequence of this interaction.^[23]

In common with biaryl N-oxides such as QUINOX,^[3] the biaryl N-oxides formed by biocatalytic DKR turned out to be effective Lewis base organocatalysts for the asymmetric allylation of aldehydes. Using the method of Hayashi et al.,^[4] allyltrichlorosilane (1.1 equiv) and the aldehyde (1.0 equiv) were stirred in either acetonitrile or dichloromethane at -45°C in the presence of 0.1–1 mol % of the N-oxide catalyst for 6 hours (Table 4). Three substituted benzaldehydes were employed (**9a–c**), and enantiomeric excesses of up to 80% were obtained in the presence of (*S*)-**4c** (0.1 mol %).

In summary, the first asymmetric synthesis of the atropisomers by dynamic kinetic resolution using biocatalysis gives access to new biaryl N-oxide scaffolds with excellent *ee* values and yields in three steps from commercially available starting materials. Structural features in the aldehydes facilitate rapid racemization at ambient temperatures required for the asymmetric biocatalytic transformation. The N-oxides act as Lewis base organocatalysts for the asymmetric allylation of aldehydes. Biocatalytic DKR offers rich possibilities for the synthesis of atropisomers without recourse to traditional resolution.

Table 4: Allylation of benzaldehydes using the compounds **4** as organocatalysts.



Entry	Catalyst	R	(S)- 10		Config.
			Conv. [%] ^[c]	<i>ee</i> [%] ^[d]	
1	(<i>R</i>)- 4b	CF ₃	15	32	<i>S</i>
2	(<i>R</i>)- 4b	H	22	34	<i>S</i>
3	(<i>R</i>)- 4b	OMe	17	17	<i>S</i>
4	(<i>S</i>)- 4c ^[a]	CF ₃	28	50	<i>R</i>
5	(<i>S</i>)- 4c ^[a]	H	66	48	<i>R</i>
6	(<i>S</i>)- 4c ^[a]	OMe	50	76	<i>R</i>
7	(<i>S</i>)- 4c ^[a,b]	OMe	27	80	<i>R</i>

[a] Catalyst has 96% *ee*. [b] 0.1 mol % catalyst loading. [c] The conversion was determined by HPLC. [d] The *ee* value was determined by HPLC on a chiral stationary phase.

Acknowledgements

This work was supported by BBSRC, EPSRC and Johnson Matthey Catalysis and Chiral Technologies. N.J.T. and J.C. are recipients of Royal Society Wolfson Research Merit Awards.

Keywords: atropisomerism · biaryls · enzymes · kinetic resolution · organocatalysis

How to cite: *Angew. Chem. Int. Ed.* **2016**, *55*, 10755–10759
Angew. Chem. **2016**, *128*, 10913–10917

- [1] M. McCarthy, P. J. Guiry, *Tetrahedron* **2001**, *57*, 3809; E. Fernández, P. J. Guiry, K. P. T. Conole, J. M. Brown, *J. Org. Chem.* **2014**, *79*, 5391.
- [2] D. Parmar, E. Sugiono, S. Raja, M. Rueping, *Chem. Rev.* **2014**, *114*, 9047.
- [3] A. V. Malkov, L. Dufková, L. Farrugia, P. Kočovský, *Angew. Chem. Int. Ed.* **2003**, *42*, 3674; A. V. Malkov, P. Kočovský, *Eur. J. Org. Chem.* **2007**, 29.
- [4] T. Shimada, A. Kina, S. Ikeda, T. Hayashi, *Org. Lett.* **2002**, *4*, 2799.
- [5] A. V. Malkov, M. Orsini, D. Pernazza, K. W. Muir, V. Langer, P. Meghani, P. Kočovský, *Org. Lett.* **2002**, *4*, 1047; A. V. Malkov, M. M. Westwater, A. Gutnov, P. Ramírez-López, F. Friscourt, A. Kadlčíková, J. Hodačová, Z. Rankovic, M. Kotora, P. Kočovský, *J. Org. Chem.* **2003**, *68*, 9659; A. V. Malkov, M. Bell, M. Vassieu, V. Bugatti, P. Kočovský, *J. Mol. Catal. A* **2003**, *196*, 179; A. V. Malkov, M. Bell, F. Castelluzzo, P. Kočovský, *Org. Lett.* **2005**, *7*, 3219; A. V. Malkov, P. Ramírez-López, L. Biedermannová, L. Rulíček, L. Dufková, M. Kotora, F. Zhu, P. Kočovský, *J. Am. Chem. Soc.* **2008**, *130*, 5341; A. V. Malkov, M. A. Kabeshov, M. Barlog, P. Kocovský, *Chem. Eur. J.* **2009**, *15*, 1570; U. Schneider, M. Sugiura, S. Kobayashi, *Tetrahedron* **2006**, *62*, 496.
- [6] N. Takenaka, R. S. Sarangthem, B. Captain, *Angew. Chem. Int. Ed.* **2008**, *47*, 9708; *Angew. Chem.* **2008**, *120*, 9854.
- [7] M. Nakajima, T. Yokota, M. Saito, S. Hashimoto, *Tetrahedron Lett.* **2004**, *45*, 61.
- [8] J. Wencel-Delord, A. Panossian, F. R. Leroux, F. Colobert, *Chem. Soc. Rev.* **2015**, *44*, 3418.
- [9] Y. Ma, S.-D. Yang, *Chem. Eur. J.* **2015**, *21*, 6673; S. Wang, J. Li, T. Miao, W. Wu, Q. Li, Y. Zhuang, Z. Zhou, L. Qiu, *Org. Lett.* **2012**,

- 14, 1966; J. Yin, S. L. Buchwald, S. Synthesis, *J. Am. Chem. Soc.* **2000**, 122, 12051; A. N. Cammidge, K. V. L. Crépy, *Chem. Commun.* **2000**, 1723.
- [10] G. Ma, M. P. Sibi, *Chem. Eur. J.* **2015**, 21, 11644; D. Gao, Q. Gu, S. You, *ACS Catal.* **2014**, 4, 2741.
- [11] M. Schlosser, F. Bailly, *J. Am. Chem. Soc.* **2006**, 128, 16042; A. Link, C. Sparr, *Angew. Chem. Int. Ed.* **2014**, 53, 5458.
- [12] S. Staniland, B. Yuan, N. Giménez-Agulló, T. Marcelli, S. C. Willies, D. M. Grainger, N. J. Turner, J. Clayden, *Chem. Eur. J.* **2014**, 20, 13084; B. Yuan, A. Page, C. P. Worrall, F. Escalettes, S. C. Willies, J. J. W. McDouall, N. J. Turner, J. Clayden, *Angew. Chem. Int. Ed.* **2010**, 49, 7010; Y. Shimada, H. Sato, S. Minowa, K. Matsumoto, *Synlett* **2008**, 367; R. J. Armstrong, M. D. Smith, *Angew. Chem. Int. Ed.* **2014**, 53, 12822; T. Hayashi, S. Niizuma, T. Kamikawa, N. Suzuki, Y. Uozumi, *J. Am. Chem. Soc.* **1995**, 117, 9101; T. Osako, Y. Uozumi, *Org. Lett.* **2014**, 16, 5866; K. Mori, Y. Ichikawa, M. Kobayashi, Y. Shibata, M. Yamanaka, T. Akiyama, *J. Am. Chem. Soc.* **2013**, 135, 3964; J. Graff, T. Debande, J. Praz, L. Guénée, A. Alexakis, *Org. Lett.* **2013**, 15, 4270; R. J. Armstrong, M. D. Smith, *Angew. Chem. Int. Ed.* **2014**, 53, 12822; *Angew. Chem.* **2014**, 126, 13036.
- [13] M. E. Diener, A. J. Metrano, S. Kusano, S. J. Miller, *J. Am. Chem. Soc.* **2015**, 137, 12369; R. Miyaji, K. Asano, S. Matsubara, *J. Am. Chem. Soc.* **2015**, 137, 6766; Y.-N. Ma, H.-Y. Zhang, S.-D. Yang, *Org. Lett.* **2015**, 17, 2034; J. Zheng, S. You, *Angew. Chem. Int. Ed.* **2014**, 53, 13244; S. Lu, S. B. Poh, Y. Zhao, *Angew. Chem. Int. Ed.* **2014**, 53, 11041; A. Ros, B. Estepa, P. Ramírez-López, E. Álvarez, R. Fernández, J. M. Lassaletta, *J. Am. Chem. Soc.* **2013**, 135, 15730; C. K. Hazra, Q. Dherbassy, J. Wencel-Delord, F. Colobert, *Angew. Chem. Int. Ed.* **2014**, 53, 13871–13875; V. Bhat, S. Wang, B. M. Stoltz, S. C. Virgil, *J. Am. Chem. Soc.* **2013**, 135, 16829.
- [14] J. Clayden, S. P. Fletcher, J. J. W. McDouall, S. J. M. Rowbottom, *J. Am. Chem. Soc.* **2009**, 131, 5331.
- [15] Y. Fujimoto, H. Iwadate, N. Ikekawa, *J. Chem. Soc. Chem. Commun.* **1985**, 1333; K. Kawahara, T. Matsumoto, H. Hashimoto, S. Miyano, *Chem. Lett.* **1988**, 1163; S. Miyano, K. Kawahara, Y. Inoue, H. Hashimoto, *Chem. Lett.* **1987**, 355; N. Aoyagi, S. Kawauchi, T. Izumi, *Tetrahedron Lett.* **2003**, 44, 5609; N. Aoyagi, T. Izumi, *Tetrahedron Lett.* **2002**, 43, 5529; T. Furutani, M. Hatsuda, R. Imashiro, M. Seki, *Tetrahedron: Asymmetry* **1999**, 10, 4763; O. Verho, J.-E. Bäckvall, *J. Am. Chem. Soc.* **2015**, 137, 3996–4009; I. Pàmies, J.-E. Bäckvall, *Chem. Rev.* **2003**, 103, 3247–3262.
- [16] B. Skrobo, J. D. Rolfes, J. Deska, *Tetrahedron* **2016**, 72, 1257.
- [17] M. Rachwalski, N. Vermue, F. P. T. J. Rutjes, *Chem. Soc. Rev.* **2013**, 42, 9268.
- [18] For related uses of this principle, see: A. Bracegirdle, J. Clayden, L. W. Lai, *Beilstein J. Org. Chem.* **2008**, 4, 47; J. Clayden, L. W. Lai, M. Helliwell, *Tetrahedron* **2004**, 60, 4399; J. Clayden, L. W. Lai, *Tetrahedron Lett.* **2001**, 42, 3163; J. Clayden, L. W. Lai, *Angew. Chem. Int. Ed.* **1999**, 38, 2556; V. Chan, J. G. Kim, C. Jimeno, P. J. Carroll, P. J. Walsh, *Org. Lett.* **2004**, 6, 2051.
- [19] R. W. Baker, S. O. Rea, M. V. Sargent, E. M. C. Schenkelaars, T. S. Tjahjandarie, A. Totaro, *Tetrahedron* **2005**, 61, 3733.
- [20] H. Li, J. Moncecchi, M. D. Truppo, *Org. Process Res. Dev.* **2015**, 19, 695; G. A. Applegate, D. B. Berkowitz, *Adv. Synth. Catal.* **2015**, 357, 1619.
- [21] C. C. Milburn, H. J. Lamble, A. Theodossis, S. D. Bull, D. W. Hough, M. J. Danson, G. L. Taylor, *J. Biol. Chem.* **2006**, 281, 14796.
- [22] R. Ruzziconi, S. Lepri, F. Buonerba, M. Schlosser, M. Mancinelli, S. Ranieri, L. Prati, A. Mazzanti, *Org. Lett.* **2015**, 17, 2740.
- [23] G. W. Breton, C. J. Crasto, *J. Org. Chem.* **2015**, 80, 7375.

Received: June 6, 2016

Published online: August 9, 2016